CL2016001041A1 - Implante intraocular biodegradable que contiene una matriz de polimero biodegradable, polietilenglicol 3350 y una prostamida; uso del mismo en la reducción de la presion ocular en el ojo de un mamifero; aparato para administrar el implante intraocular biodegradable; y método para confeccionar un implante intraocular biodegradable. - Google Patents

Implante intraocular biodegradable que contiene una matriz de polimero biodegradable, polietilenglicol 3350 y una prostamida; uso del mismo en la reducción de la presion ocular en el ojo de un mamifero; aparato para administrar el implante intraocular biodegradable; y método para confeccionar un implante intraocular biodegradable.

Info

Publication number
CL2016001041A1
CL2016001041A1 CL2016001041A CL2016001041A CL2016001041A1 CL 2016001041 A1 CL2016001041 A1 CL 2016001041A1 CL 2016001041 A CL2016001041 A CL 2016001041A CL 2016001041 A CL2016001041 A CL 2016001041A CL 2016001041 A1 CL2016001041 A1 CL 2016001041A1
Authority
CL
Chile
Prior art keywords
intraocular implant
biodegradable
eye
biodegradable intraocular
prostamide
Prior art date
Application number
CL2016001041A
Other languages
English (en)
Inventor
Alazar N Ghebremeskel
Michael R Robinson
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CL2016001041A1 publication Critical patent/CL2016001041A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/14—Eye parts, e.g. lenses or corneal implants; Artificial eyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)
  • Polyesters Or Polycarbonates (AREA)

Abstract

Un implante intraocular biodegradable para reducir la presión intraocular (lOP) en un ojo, donde el implante comprende una matriz de polimero biodegradable, polietilenglicol 3350 y una prostamida como el agente activo, donde la prostamida y el polietilenglicol 3350 se asocian con la matriz de polímero biodegradable; metodo para la reduccion de la presion ocular; y aparato para administrar un implante ocular.
CL2016001041A 2013-10-31 2016-04-29 Implante intraocular biodegradable que contiene una matriz de polimero biodegradable, polietilenglicol 3350 y una prostamida; uso del mismo en la reducción de la presion ocular en el ojo de un mamifero; aparato para administrar el implante intraocular biodegradable; y método para confeccionar un implante intraocular biodegradable. CL2016001041A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361898241P 2013-10-31 2013-10-31

Publications (1)

Publication Number Publication Date
CL2016001041A1 true CL2016001041A1 (es) 2016-10-28

Family

ID=51982758

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001041A CL2016001041A1 (es) 2013-10-31 2016-04-29 Implante intraocular biodegradable que contiene una matriz de polimero biodegradable, polietilenglicol 3350 y una prostamida; uso del mismo en la reducción de la presion ocular en el ojo de un mamifero; aparato para administrar el implante intraocular biodegradable; y método para confeccionar un implante intraocular biodegradable.

Country Status (28)

Country Link
US (6) US9492316B2 (es)
EP (5) EP3669865A1 (es)
JP (2) JP6482547B2 (es)
KR (1) KR102307281B1 (es)
CN (2) CN105682645B (es)
AU (3) AU2014342017B2 (es)
BR (1) BR112016009575B1 (es)
CA (1) CA2926515C (es)
CL (1) CL2016001041A1 (es)
CY (2) CY1119961T1 (es)
DK (2) DK3062775T3 (es)
ES (2) ES2805880T3 (es)
HU (2) HUE036554T2 (es)
IL (2) IL244859B (es)
MX (2) MX2016005508A (es)
MY (1) MY177958A (es)
NO (1) NO3102476T3 (es)
PH (1) PH12016500767B1 (es)
PL (2) PL3351239T3 (es)
PT (2) PT3351239T (es)
RU (1) RU2650614C2 (es)
SA (1) SA516371022B1 (es)
SG (2) SG11201603383VA (es)
SI (2) SI3062775T1 (es)
TR (1) TR201802759T4 (es)
UA (1) UA119853C2 (es)
WO (1) WO2015066548A1 (es)
ZA (1) ZA201602556B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US8846073B2 (en) * 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
CA2762536C (en) 2009-05-18 2019-05-21 Dose Medical Corporation Drug eluting ocular implant
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
EP2654715B1 (en) 2010-11-24 2017-01-25 Dose Medical Corporation Drug eluting ocular implant
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
SG11201603383VA (en) * 2013-10-31 2016-05-30 Allergan Inc Prostamide-containing intraocular implants and methods of use thereof
WO2015085251A1 (en) * 2013-12-06 2015-06-11 Envisia Therapeutics Inc. Intracameral implant for treatment of an ocular condition
US20150342875A1 (en) 2014-05-29 2015-12-03 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
CA2978600A1 (en) 2015-03-06 2016-09-15 Envisia Therapeutics, Inc. Implant applicators and methods of administering implants
EP3324890A4 (en) * 2015-07-23 2019-06-19 Allergan, Inc. GLACO-TREATMENT VIA INTRAKAMERAL EYE IMPLANTS
JP6914931B2 (ja) 2015-07-23 2021-08-04 アエリエ ファーマシューティカルズ インコーポレイテッド 眼の症状の治療のための医薬組成物、硝子体内インプラント及び医薬品の製造におけるそれらの使用
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
KR20180058758A (ko) 2015-09-22 2018-06-01 그레이버그 비젼, 인크. 안구 장애의 치료를 위한 화합물 및 조성물
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
JP7003110B2 (ja) 2016-04-20 2022-01-20 ドーズ メディカル コーポレーション 生体吸収性眼球薬物送達デバイス
JP2019518546A (ja) 2016-05-31 2019-07-04 キュラ, インク.Qura, Inc. 埋込型眼圧センサ及び使用方法
CN109890333A (zh) 2016-09-02 2019-06-14 爱瑞制药公司 植入物涂敷器
US20190192341A1 (en) * 2017-11-09 2019-06-27 Allergan, Inc. Sustained-Release Implants for Lowering Intraocular Pressure with Extended Duration of Effect
CN112566622A (zh) * 2018-06-19 2021-03-26 细胞疗法有限责任公司 用于治疗青光眼或高眼压症的包含眼内压降低剂、cnp化合物、npr-b化合物、tie-2激动剂或神经营养剂的缓释药物递送系统
WO2020047144A2 (en) * 2018-08-30 2020-03-05 Liu Yunxiang Ophthalmic formulations, process for preparing the same and method for administering the same
AU2019400857B2 (en) * 2018-12-21 2025-09-04 Re-Vana Therapeutics Ltd Coated ocular implants
US12491263B2 (en) * 2019-05-13 2025-12-09 University of Pittsburgh—of the Commonwealth System of Higher Education Polymer-based implant for retinal therapy and methods of making and using the same
GB2601922B (en) 2019-06-27 2024-04-24 Layerbio Inc Ocular device drub delivery systems
IL295357B1 (en) 2020-02-06 2025-12-01 Ocular Therapeutix Inc Travoprost sustained-release biodegradable intracameral implants for use in the treatment of ocular diseases
EP3936113A1 (en) * 2020-07-07 2022-01-12 Occlugel Hydrophilic degradable microsphere for delivering travoprost
EP4178506A1 (en) 2020-07-10 2023-05-17 Allergan, Inc. Posterior chamber delivery device for sustained release implant
EP4185299A1 (en) * 2020-07-21 2023-05-31 Allergan, Inc. Intraocular implant with high loading of a prostamide
BR112023022705A2 (pt) 2021-04-30 2024-01-16 Perfuse Therapeutics Inc Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares
US12458535B1 (en) 2025-04-25 2025-11-04 Michael Reynard Endothelial-integrated stent for Schlemm's canal and controlled aqueous humor outflow

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3749776A (en) 1970-08-28 1973-07-31 Allergan Pharma Method for blocking prostaglandin activity
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
CA1311686C (en) 1986-06-25 1992-12-22 John Weldon Shell Controlled release bioerodible drug delivery system
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
CA2021316C (en) 1989-07-27 2000-10-24 Ming Fai Chan Intraocular pressure reducing 11-acyl prostaglandins
US5028624A (en) 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
US5034413A (en) 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
US4994274A (en) 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US6602900B2 (en) 1992-09-21 2003-08-05 Allergan, Inc. Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5834498A (en) 1992-09-21 1998-11-10 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
MY113268A (en) 1992-12-29 2002-01-31 Insite Vision Incorporated Plasticized bioerodible controlled delivery system
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5545665A (en) 1993-12-28 1996-08-13 Allergan Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
US6124344A (en) 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5516522A (en) 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US5585401A (en) 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
US6369116B1 (en) 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
US5741810A (en) 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
US6395787B1 (en) 2000-02-08 2002-05-28 Allergan Sales, Inc. Ocular hypotensive lipids
US7708711B2 (en) 2000-04-14 2010-05-04 Glaukos Corporation Ocular implant with therapeutic agents and methods thereof
US20040175410A1 (en) 2000-04-26 2004-09-09 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
PE20020146A1 (es) 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
WO2002005853A2 (en) 2000-07-14 2002-01-24 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
WO2002043785A2 (en) 2000-11-29 2002-06-06 Oculex Pharmaceuticals, Inc. Intraocular implants for preventing transplant rejection in the eye
WO2002089767A1 (en) 2001-05-03 2002-11-14 Massachusetts Eye And Ear Infirmary Implantable drug delivery device and use thereof
US20030220376A1 (en) 2001-08-10 2003-11-27 Pharmacia Corporation Methods for treating carbonic anhydrase mediated disorders
GB0122318D0 (en) 2001-09-14 2001-11-07 Novartis Ag Organic compounds
TWI337881B (en) 2002-08-29 2011-03-01 Santen Pharmaceutical Co Ltd Treating agent for glaucoma comprising rho kinase inhibitor and prostaglandin
US6899717B2 (en) 2002-09-18 2005-05-31 Allergan, Inc. Methods and apparatus for delivery of ocular implants
DE60325511D1 (de) 2002-11-06 2009-02-05 Alza Corp Depot-formulierungen mit verzögerter freisetzung
US20040137059A1 (en) * 2003-01-09 2004-07-15 Thierry Nivaggioli Biodegradable ocular implant
US20090148527A1 (en) 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
US7169807B2 (en) 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US20050244458A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US20230026451A1 (en) * 2004-04-30 2023-01-26 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20060182781A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US7589057B2 (en) 2004-04-30 2009-09-15 Allergan, Inc. Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US9498457B2 (en) * 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20070212395A1 (en) 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US20050282902A1 (en) 2004-06-22 2005-12-22 Allergan, Inc. Abnormal cannabidiols as agents for lowering intraocular pressure
US7101904B2 (en) 2004-08-10 2006-09-05 Allergan, Inc. Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US7473738B2 (en) * 2004-09-30 2009-01-06 Johnson & Johnson Vision Care, Inc. Lactam polymer derivatives
CN101437478A (zh) * 2004-10-04 2009-05-20 Qlt美国有限公司 聚合送递制剂的眼部送递
EP1804751A2 (en) 2004-10-04 2007-07-11 QLT USA, Inc. Ocular delivery of polymeric delivery formulations
US7101906B2 (en) 2004-11-16 2006-09-05 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US7183324B2 (en) 2004-11-23 2007-02-27 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
BRPI0605926A2 (pt) 2005-01-14 2009-05-26 Allergan Inc ciclopentanos substituìdos ou ciclopentanonas como agentes terapêuticos
CN101137622A (zh) 2005-03-10 2008-03-05 阿勒根公司 作为治疗剂的取代的γ内酰胺
CA2602535A1 (en) 2005-05-06 2006-11-16 Allergan, Inc. Substituted beta-lactams and their use in medicine
WO2007005176A1 (en) 2005-06-29 2007-01-11 Allergan, Inc. Pyrrolidinones for the treatment of glaucoma and ocular hypertension
DE102005033101A1 (de) 2005-07-15 2007-01-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Resorbierbare Polyetherester und ihre Verwendung zur Herstellung von medizinischen Implantaten
CA2850858A1 (en) 2005-09-16 2007-04-05 Allergan, Inc. Compositions and methods for the intraocular transport of therapeutic agents
US20090082321A1 (en) 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
EP2628725A1 (en) 2005-11-03 2013-08-21 Allergan, Inc. Prostaglandins and analogues as agents for lowering intraocular pressure
PE20080142A1 (es) 2006-03-15 2008-04-14 Boehringer Ingelheim Int Beta-agonistas enantiomericamente puros y sus procedimientos de preparacion
AU2007226957B2 (en) 2006-03-20 2013-08-15 Allergan, Inc. Substituted gamma lactams as prostaglandin EP2 agonists
US7439372B2 (en) 2006-05-03 2008-10-21 Allergan, Inc. Therapeutic compounds
US7491844B2 (en) 2006-05-04 2009-02-17 Allergan, Inc. Therapeutic cyclopentane derivatives
US20070293873A1 (en) 2006-06-19 2007-12-20 Allergan, Inc. Apparatus and methods for implanting particulate ocular implants
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20070298073A1 (en) 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US9039761B2 (en) * 2006-08-04 2015-05-26 Allergan, Inc. Ocular implant delivery assemblies with distal caps
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8846073B2 (en) 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
US8231892B2 (en) 2007-05-24 2012-07-31 Allergan, Inc. Biodegradable drug delivery system
US20090081277A1 (en) 2007-09-21 2009-03-26 Allergan, Inc. Pharmaceutical formulations and methods for treating ocular conditions
US7740604B2 (en) 2007-09-24 2010-06-22 Ivantis, Inc. Ocular implants for placement in schlemm's canal
EP2296621A1 (en) 2008-05-20 2011-03-23 Yale University Biodegradable sustained-release polymeric microparticulates comprising a hydrophobic drug and determined for ophthalmic use
US20100098772A1 (en) 2008-10-21 2010-04-22 Allergan, Inc. Drug delivery systems and methods for treating neovascularization
US20100104654A1 (en) * 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
EP2389221B1 (en) * 2009-01-23 2023-08-16 Mati Therapeutics Inc. Sustained released delivery of one or more agents
US20100247606A1 (en) 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
EP2512389B1 (en) 2009-12-16 2015-09-02 Allergan, Inc. Intracameral devices for sustained delivery
KR20180117211A (ko) * 2010-01-22 2018-10-26 알러간, 인코포레이티드 전방내 서방성 치료제 이식물
WO2011109384A2 (en) * 2010-03-02 2011-09-09 Allergan, Inc. Biodegradable polymers for lowering intraocular pressure
CN103619837A (zh) 2011-04-22 2014-03-05 阿勒根公司 用于治疗疼痛的脂肪酸酰胺水解酶抑制剂
US8715713B2 (en) 2011-04-29 2014-05-06 Allergan, Inc. Solvent cast film sustained release latanoprost implant
SG11201603383VA (en) * 2013-10-31 2016-05-30 Allergan Inc Prostamide-containing intraocular implants and methods of use thereof
US20190192341A1 (en) * 2017-11-09 2019-06-27 Allergan, Inc. Sustained-Release Implants for Lowering Intraocular Pressure with Extended Duration of Effect
EP4185299A1 (en) * 2020-07-21 2023-05-31 Allergan, Inc. Intraocular implant with high loading of a prostamide

Also Published As

Publication number Publication date
US20180271878A1 (en) 2018-09-27
US20170056412A1 (en) 2017-03-02
NO3102476T3 (es) 2018-05-26
SG10201800978UA (en) 2018-03-28
EP3351239B1 (en) 2020-04-01
UA119853C2 (uk) 2019-08-27
US20210030766A1 (en) 2021-02-04
US20220218721A1 (en) 2022-07-14
NZ718992A (en) 2021-11-26
US20240108635A1 (en) 2024-04-04
KR102307281B1 (ko) 2021-09-29
RU2650614C2 (ru) 2018-04-16
EP4046628A1 (en) 2022-08-24
EP3669865A1 (en) 2020-06-24
PT3351239T (pt) 2020-07-03
EP3062775B1 (en) 2017-12-06
DK3062775T3 (en) 2018-03-12
TR201802759T4 (tr) 2018-03-21
EP3062775A1 (en) 2016-09-07
AU2014342017A1 (en) 2016-06-02
PH12016500767A1 (en) 2016-06-20
JP6482547B2 (ja) 2019-03-13
IL244859B (en) 2019-08-29
US20150118279A1 (en) 2015-04-30
HK1258014A1 (en) 2019-11-01
PH12016500767B1 (en) 2016-06-20
RU2016116378A (ru) 2017-12-01
AU2020201778B2 (en) 2021-11-04
ES2661666T3 (es) 2018-04-03
MY177958A (en) 2020-09-28
US9492316B2 (en) 2016-11-15
IL244859A0 (en) 2016-05-31
CY1119961T1 (el) 2018-12-12
ES2805880T3 (es) 2021-02-15
SA516371022B1 (ar) 2018-03-04
PL3351239T3 (pl) 2020-12-28
SI3062775T1 (en) 2018-05-31
US9980974B2 (en) 2018-05-29
ZA201602556B (en) 2017-06-28
JP6814829B2 (ja) 2021-01-20
CN110302138B (zh) 2022-09-30
HUE050902T2 (hu) 2021-01-28
AU2014342017B2 (en) 2020-01-23
PT3062775T (pt) 2018-03-06
MX2020002381A (es) 2020-07-22
JP2017500282A (ja) 2017-01-05
CN110302138A (zh) 2019-10-08
EP4406535A2 (en) 2024-07-31
CN105682645A (zh) 2016-06-15
PL3062775T3 (pl) 2018-05-30
KR20160077121A (ko) 2016-07-01
SI3351239T1 (sl) 2020-09-30
BR112016009575B1 (pt) 2022-12-13
DK3351239T3 (da) 2020-06-29
SG11201603383VA (en) 2016-05-30
JP2019088881A (ja) 2019-06-13
HUE036554T2 (hu) 2018-07-30
CA2926515A1 (en) 2015-05-07
AU2022200742B2 (en) 2024-08-22
AU2020201778A1 (en) 2020-03-26
AU2022200742A1 (en) 2022-02-24
IL268976B (en) 2021-04-29
WO2015066548A1 (en) 2015-05-07
BR112016009575A2 (pt) 2017-08-01
CA2926515C (en) 2020-11-24
MX2016005508A (es) 2016-08-03
CY1123077T1 (el) 2021-10-29
IL268976A (en) 2019-10-31
EP3351239A1 (en) 2018-07-25
EP4406535A3 (en) 2024-11-06
CN105682645B (zh) 2019-09-06

Similar Documents

Publication Publication Date Title
CL2016001041A1 (es) Implante intraocular biodegradable que contiene una matriz de polimero biodegradable, polietilenglicol 3350 y una prostamida; uso del mismo en la reducción de la presion ocular en el ojo de un mamifero; aparato para administrar el implante intraocular biodegradable; y método para confeccionar un implante intraocular biodegradable.
CL2016001160A1 (es) Dispositivo intraocular de suministro de fármacos de liberación sostenida configurado para el surco de los ojos, que comprende un núcleo de matriz polimérica con agente terapéutico y un revestimiento polimérico que rodea a la matriz y el dispositivo se forma de un segmento anular con un diámetro de sección transversal que varía de 0,10-0,80 mm.
AR086945A1 (es) Material polimerico para un recipiente aislante
CO7151487A2 (es) Formulación de anticuerpos
AR107967A1 (es) Ácido hialurónico modificado, método para su preparación y usos del mismo
MX2018014763A (es) Suministro intraocular de farmacos.
AR112286A2 (es) Sistema polimérico de lágrimas artificiales
AR093151A1 (es) Material polimerico para aislacion de recipientes
CO2017005624A2 (es) Composiciones oftálmicas estabilizadas de omega 3
MX2016006620A (es) Receptores de células t humanas con alta afinidad modificados por medio de manipulación genetica.
TW201613588A (en) Ophthalmic composition
MX2016007681A (es) Sistema de administracion farmacologico.
BR112015019546A2 (pt) implante de distribuição de drogas prolongado
DOP2016000061A (es) Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso
PE20150958A1 (es) Soluciones midriaticas y antiinflamatorias inyectables, estables y libres de conservantes
AR073460A1 (es) Dispositivo oftalmico con capacidad de administracion de agente terapeutico y metodo de formacion del mismo
BR112016010103A8 (pt) métodos, kits e dispositivos de suprimento de fármaco osmótico.
CL2017001964A1 (es) Encapsulado de agentes activos de alta potencia.
CO7190239A2 (es) Dialisato a base de polímero
MX2019006291A (es) Composiciones de lactato de calcio y metodos de uso.
CO7071123A2 (es) Formulaciones basadas en dispersiones solidas
AR090930A1 (es) Composiciones oftalmicas con proteccion mejorada contra la desecacion y retencion
MX2016012823A (es) Inserto vaginal.
AR101236A1 (es) Composiciones para el cuidado oral
AR096313A1 (es) Vendaje para herida que comprende una composición antimicrobiana